Clinical trial
A Phase 3 Study of Talaporfin Sodium and Interstitial Light Emitting Diodes…
NCT00355355 · Light Sciences Oncology, Industry · Completed
Key facts
| NCT number | NCT00355355 |
|---|---|
| Title | A Phase 3 Study of Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC) |
| Official title | A Phase 3 Randomized Study to Evaluate Survival of Patients Treated With Talaporfin Sodium (LS11) and Interstitial Light Emitting Diodes (LED) as Compared to the Standard of Care Therapies in the Treatment of Unresectable Hepatocellular Carcinoma (HCC) |
| Lead sponsor | Light Sciences Oncology, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Hepatocellular, Liver Neoplasms |
| Intervention type | Device, Drug, Procedure |
| Interventions | Talaporfin sodium, Interstitial Light Emitting Diodes, Percutaneous placement of device in the liver, Standard Care |
| Enrollment | 208 |
| Start date | Jul 1, 2006 |
| Primary completion | Sep 1, 2012 |
| Completion | Sep 1, 2012 |
| First posted | Jul 21, 2006 |
| Last update posted | Jan 30, 2015 |
| Countries | Croatia, Hong Kong, India, Malaysia, Philippines, Poland, Serbia, Singapore, South Korea, Sweden, Thailand |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: